Parnassus Mid Cap Growth Fund (Investor Shares) returned 7.90% (net of fees) for the quarter, outperforming the Russell Midcap Growth Index’s 2.78% return. Read more here.

While tariff threats and drug pricing pressures weighed on healthcare stocks' outlook, some parts of the sector are beginning to stage a recovery. TD Asset Management's Ram Sampath discusses ...

Treasuries gained after a reading on inflation came in as expected, leaving the Federal Reserve on track to continue cutting interest rates next month. The gains pushed down yields by about one basis ...

US personal spending rose at a solid clip for a third month in August, suggesting consumers continued to power the economy despite elevated inflation. Consumer spending, adjusted for changes in prices ...

A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike ...

While Ozempic and other drugs like it have proven effective in helping people lose weight, many gain it back when the injections stop. A new drug targets weight loss differently, leading to a more ...

A new era of weight-loss treatment could soon trade needles for pills. Drugmakers behind GLP-1 injections like Wegovy and Zepbound are racing to launch once-daily oral versions that may help people ...

An intriguing new option is coming for weight-loss drugs: a pill that you take once a day to shed pounds, rather than the weekly injections that have powered the anti-obesity revolution up to now. The ...

Novo Nordisk said that patients taking a pill form of Wegovy in a clinical trial lost about as much weight as those who get the shot version, fueling new optimism that oral GLP-1 drugs could expand an ...

Charlotte Lee does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

A GLP-1 drug called orforglipron—taken in pill form once a day—has been shown to help with "significant" weight loss in people with obesity. In a multinational trial of around 3,000 adults, a 72-week ...

FDA's new voucher could shorten drug review to 1-2 months Lilly's orforglipron targets high-burden chronic condition Analysts predict price erosion due to new market entrants Sept 16 (Reuters) - Eli ...